全文获取类型
收费全文 | 4862篇 |
免费 | 307篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 70篇 |
儿科学 | 117篇 |
妇产科学 | 53篇 |
基础医学 | 528篇 |
口腔科学 | 167篇 |
临床医学 | 324篇 |
内科学 | 1324篇 |
皮肤病学 | 96篇 |
神经病学 | 345篇 |
特种医学 | 130篇 |
外科学 | 937篇 |
综合类 | 13篇 |
预防医学 | 99篇 |
眼科学 | 72篇 |
药学 | 357篇 |
中国医学 | 11篇 |
肿瘤学 | 563篇 |
出版年
2023年 | 73篇 |
2022年 | 119篇 |
2021年 | 203篇 |
2020年 | 111篇 |
2019年 | 147篇 |
2018年 | 169篇 |
2017年 | 128篇 |
2016年 | 145篇 |
2015年 | 145篇 |
2014年 | 171篇 |
2013年 | 206篇 |
2012年 | 335篇 |
2011年 | 330篇 |
2010年 | 149篇 |
2009年 | 128篇 |
2008年 | 235篇 |
2007年 | 226篇 |
2006年 | 221篇 |
2005年 | 175篇 |
2004年 | 163篇 |
2003年 | 173篇 |
2002年 | 147篇 |
2001年 | 91篇 |
2000年 | 106篇 |
1999年 | 100篇 |
1998年 | 40篇 |
1997年 | 36篇 |
1996年 | 29篇 |
1995年 | 32篇 |
1994年 | 28篇 |
1993年 | 33篇 |
1992年 | 80篇 |
1991年 | 94篇 |
1990年 | 68篇 |
1989年 | 57篇 |
1988年 | 61篇 |
1987年 | 59篇 |
1986年 | 59篇 |
1985年 | 50篇 |
1984年 | 39篇 |
1983年 | 26篇 |
1982年 | 19篇 |
1981年 | 19篇 |
1979年 | 18篇 |
1978年 | 18篇 |
1976年 | 17篇 |
1975年 | 14篇 |
1974年 | 16篇 |
1973年 | 10篇 |
1967年 | 13篇 |
排序方式: 共有5206条查询结果,搜索用时 0 毫秒
51.
An alternative method of arterial reconstruction after hepatic arterial thrombosis following living-related liver transplantation 总被引:4,自引:0,他引:4
Ikegami T Kawasaki S Hashikura Y Miwa S Kubota T Mita A Iijima S Terada M Miyagawa S Furuta S 《Transplantation》2000,69(9):1953-1955
BACKGROUND: Hepatic artery thrombosis (HAT) remains an important cause of graft loss after liver transplantation. Emergency rearterialization methods are limited in cases of living-related liver transplantation in which the graft hepatic artery is thin and short. CASE: A 19-year-old woman who underwent living-related liver transplantation for biliary atresia developed HAT on the 4th postoperative day. During the emergency laparotomy the recipient hepatic artery was found to be too short to anastomose, so the recipient's right gastroepiploic artery was anastomosed to the graft hepatic artery. The patient is now alive and well 6 months after reoperation, and she has experienced no further episode of HAT. CONCLUSION: The right gastroepiploic artery can be used easily and safely for hepatic graft revascularization without causing ischemia of the stomach. An additional skin incision is not required, and the artery is long enough to anastomose to the graft artery directly. The method of hepatic graft rearterialization described here is an important option for patients who undergo living-related or split liver transplantation. 相似文献
52.
Shunsuke Okazaki 《SANGYO EISEIGAKU ZASSHI》2005,47(1):33-39
In 1992, Brugada et al. reported a characteristic electrocardiogram (ECG) pattern and ST-segment elevation in leads V1 to V3 associated with sudden death in patients without demonstrable structural heart disease. That disease is now called Brugada Syndrome. The diagnostic criteria for the Brugada Syndrome have still not been decided on, and the prevalence of Brugada type ECG (B-ECG) varies widely in Japan. Therefore, we should consider B-ECG according to the consensus statement from the European Society of Cardiology and we proposed its management in health examinations. There were 35 B-ECG cases (0.9%), all male out of 3,875 Postal Service Trainees. There were 5 cases of Type I (Coved) (0.13%), 21 cases of Type II (0.54%), and 9 cases of Type III (0.23%), Only one case (0.026%) of Brugada Syndrome was found, and eventually, he received an Implantable Cardioverter Defibrillator (ICD). Type I (Coved) may be a more important electrocardiographic factor having a stronger causal relation to Ventricular Arrhythmia. Therefore, in management of health examinations, Type I patients with syncope or a family history of sudden cardiac death should visit a cardiologist for ICD-implantation, and even without any cardiac symptoms (syncope and a family history of sudden death), they are advised to visit a cardiologist for a program electrical stimulation (PES). Type II and III patients with any cardiac symptoms are advised to visit a cardiologist for PES or a drug challenge. 相似文献
53.
Hinokio Y Horikawa Y Furuta H Cox NJ Iwasaki N Honda M Ogata M Iwamoto Y Bell GI 《Diabetes》2000,49(2):302-305
54.
Hatano T Igarashi H Nakada J Oishi Y Yanada S Furuta A Takizawa A Iwamuro S Tashiro K 《Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology》2000,91(6):542-546
BACKGROUND: Luteinizing hormone-releasing hormone (LHRH) agonists are popularly used drugs in the treatment of prostatic cancer. However, it has been reported that continuation of a low testosterone level following a longterm administration of these drugs reduces the bone mineral density and makes for osteoporosis, which is accountable for fracture, we measured the bone mineral density and bone metabolic markers in the cases who suffered fracture receiving LHRH agonists for prostatic cancer. PATIENTS AND METHODS: Between 1994 and 1998, 196 patients (mean age 78.1 years) were treated with LHRH agonists for prostatic cancer. Of these patients, 13(7%) who had bone fracture during treated with LHRH agonists were divided into fracture group, and 70 patients who had not bone fracture divided into non-fracture group. Fracture by traffic accident was excluded. The bone density in the third lumbar vertebra was measured using quantitative computed tomography (QCT). Osteocalcin, 1, 25- (OH)2 vitamin D, urinary type 1 collagen cross-linked N-telopeptides (NTx), parathyroid hormone (PTH) and calcitonin were measured as bone metabolic markers. RESULTS: The mean age of fractured cases was 78 years. The period from the start of treatment to fracture was 11 to 45 months (mean 27 months). No case of fracture at the site of metastasis of prostatic cancer was found. The bone density was significantly low in the fracture group compared with that of non-fracture group. Of the bone metabolic markers, NTx showed high values in the fracture group. CONCLUSION: There is a need to measure bone mineral density and bone metabolic markers periodically and to evaluate secondary osteoporosis in the patients receiving LHRH agonists for prostatic cancer. 相似文献
55.
Shunsuke Ogata Yoshito Ishii Keiichiro Asano Erena Kobayashi Shun Kubota Keita Takahashi Yosuke Miyaji Yuichi Higashiyama Hideto Joki Hiroshi Doi Michiaki Koga Hideyuki Takeuchi Fumiaki Tanaka 《Internal medicine (Tokyo, Japan)》2022,61(11):1757
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia. 相似文献
56.
57.
Yuki Yajima Akemi Kosaka Kei Ishibashi Shunsuke Yasuda Hiroki Komatsuda Toshihiro Nagato Kensuke Oikawa Masahiro Kitada Masanori Takekawa Takumi Kumai Kenzo Ohara Takayuki Ohkuri Hiroya Kobayashi 《Cancer science》2022,113(8):2526
Although neoantigens are one of the most favorable targets in cancer immunotherapy, it is less versatile and costly to apply neoantigen‐derived cancer vaccines to patients due to individual variation. It is, therefore, important to find highly immunogenic antigens between tumor‐specific or associated antigens that are shared among patients. Considering the cancer immunoediting theory, immunogenic tumor cells cannot survive in the early phase of tumor progression including two processes: elimination and equilibrium. We hypothesized that highly immunogenic molecules are allowed to be expressed in tumor cells after an immune suppressive tumor microenvironment was established, if these molecules contribute to tumor survival. In the current study, we focused on TWIST1 as a candidate for highly immunogenic antigens because it is upregulated in tumor cells under hypoxia and promotes tumor metastasis, which is observed in the late phase of tumor progression. We demonstrated that TWIST1 had an immunogenic peptide sequence TWIST1140–162, which effectively activated TWIST1‐specific CD4+ T‐cells. In a short‐term culture system, we detected more TWIST1‐specific responses in breast cancer patients compared with in healthy donors. Vaccination with the TWIST1 peptide also showed efficient expansion of TWIST1‐reactive HTLs in humanized mice. These findings indicate that TWIST1 is a highly immunogenic shared antigen and a favorable target for cancer immunotherapy. 相似文献
58.
The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine 总被引:1,自引:0,他引:1
Shu H Hayashida M Huang W An K Chiba S Hanaoka K Arita H 《Journal of ethnopharmacology》2008,117(1):158-165
In the previous studies, we demonstrated that an oriental herbal medicine, processed Aconiti tuber (PAT), at subanalgesic doses could inhibit or reverse the antinociceptive tolerance to morphine. In the present study, we compared the effect of PAT, trans-(+/-)-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidin)cyclohexyl)-benzeneacetamide methane sulfonate hydrate (U50488H), a selective kappa opioid receptor (KOR) agonist, and (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-maleate (MK-801), a N-methyl-D-aspartate (NMDA) receptor antagonist, on the antinociceptive tolerance to morphine in the same experimental condition. Mice received subcutaneous morphine (10 mg/kg), and oral PAT at a subanalgesic dose (0.3 g/kg for mechanical or 1.0 g/kg for thermal test), or intraperitoneal U50488H at a subanalgesic dose (3 mg/kg), or MK-801 at a subanalgesic dose (0.1 mg/kg) once daily for 14 days. The mechanical nociceptive threshold was measured before, and at 60 min by tail pressure testing, and thermal nociceptive latency was measured before, and at 30 min by hot plate testing, after daily morphine injections. PAT and U50488H could not only inhibit the development of morphine tolerance but also reverse the already-developed morphine tolerance, while MK-801 could only inhibit the development of morphine tolerance but not reverse the already-developed morphine tolerance, in both mechanical and thermal nociceptive tests. These data suggested that PAT, an indirect-acting KOR agonist, share the common pharmacological property of KOR agonists on morphine tolerance, and that PAT may be superior to some NMDA receptor antagonists which do not reverse already-developed morphine tolerance. 相似文献
59.
Seigo Okada Yuji Ohnishi Takashi Furuta Yasuo Suzuki Akiko Kawakami-Miyake Chie Matsuguma Takako Waniishi Hiroki Yasudo Shunji Hasegawa 《World journal of pediatrics : WJP》2021,(6):671-673
Although the standard treatment for Kawasaki disease (KD)is intravenous immunoglobulin (IVIG) combined with oral aspirin,18% of 1st IVIG is refractory [1].Recen... 相似文献
60.
Hiroshi Yamasaki Naonobu Futamura Itaru Funakawa Nobuo Kohara Shunsuke Yoshimura Masakatsu Motomura 《Internal medicine (Tokyo, Japan)》2022,61(7):1063
We herein report two P/Q-type voltage-gated calcium channel (VGCC) antibody-positive Lambert-Eaton myasthenic syndrome (LEMS) patients who responded dramatically to cholinesterase inhibitors. Patient 1, a 76-year-old man, had small-cell lung cancer and developed LEMS during chemotherapy. When symptomatic treatment was started with pyridostigmine, gait disturbance was ameliorated, and his modified Rankin scale decreased from 4 points to 3 points. Patient 2, a 68-year-old man, had cancer-free LEMS. Distigmine bromide was very effective and ameliorated not only his gait disturbance but also autonomic symptoms, and his modified Rankin scale decreased from 2 points to 1 point. Cholinesterase inhibitors alone may be effective in a small portion of LEMS patients. 相似文献